Canatu’s key strengths

1. Versatile platform technology leading the next wave of material transformation
2. Scalable business models
3. Deep customer integration and Dry Deposition platform creates high switching costs
4. CNT pellicle technology moves from validation to scaling
5. Market drivers support growth in the energy-optimized automotive market
6. Clear benefits supporting potential market shift from centralized to point-of-care testing
7. Addressing large and growing markets estimated to reach ~3B€ in 2030
8. Focused execution and disciplined capital allocation
9. 100-150M€ revenue target and 25-30% EBIT margin in 2030

1. Versatile platform technology leading the next wave of material transformation

Canatu’s key strength lies in its unique carbon nanotube (CNT) technology platform, creating a strong competitive advantage. The company’s strategic theme, moving from technology validation to scalable value creation, reflects its direction.

Legacy materials are reaching their limits, driven by demand for higher performance and energy efficiency. Canatu is leading the next wave of material transformation as legacy materials reach their limits, under growing demands for higher performance and energy efficiency. CNTs are a next-generation general-purpose technology with broad application potential, enabling step-change improvements in performance.

2. Scalable business models

Canatu operates through two business models: selling CNT products directly and selling CNT reactors while licensing the related technology, allowing customers to produce CNT products under a limited license.

Canatu’s scalable business models enable flexibility, allowing it to address both niche, high-margin opportunities and global, high-volume cases.

3. Deep customer integration and Dry Deposition platform creates high switching costs

Canatu’s business model leverages its efficient and proprietary Dry Deposition™ CNT technology platform. Whether selling CNT products or selling CNT reactors and licensing technology, this platform supports asset-light growth and offers strong gross margin potential in the semiconductor, automotive, and medical diagnostics industries.

4. CNT pellicle technology moves from validation to scaling

Semiconductors are Canatu’s key growth driver, supporting the transition to a predominantly recurring revenue model in 2030. The key business target is to become the leading provider of CNT pellicle membrane technology for EUV lithography. CNT pellicle technology is moving from validation to scaling, with the EUV pellicle market representing the largest near- and mid-term opportunity for Canatu.

5. Market drivers support growth in the energy-optimized automotive market

Automotive electrification increases the need for smarter thermal energy optimization, while higher levels of advanced driver assistance systems (ADAS) require sensors with increasingly stringent optical performance. In Automotive, Canatu’s target is to establish a position in the fast-growing full-windshield market, and as a supplier of ADAS camera heaters. Priority applications include ADAS camera heaters, full windshield heaters, and solar cells, with commercialization progressing in phases.

The key operational goal is to start mass production of ADAS camera heaters with the lead customer and scale in phases toward a sustained camera heater business. In parallel, Canatu continues focused development of additional high-value applications, including full windshield heaters and solar cells, targeting commercialization toward the end of the strategic period.

6. Clear benefits supporting potential market shift from centralized to point-of-care testing

In healthcare, the shift from centralized laboratories toward the patient’s side is driving demand for ultra-sensitive, cost-efficient, and rapid point-of-care diagnostics. In Medical Diagnostics, Canatu’s business target is to become a leading provider of point-of-care solutions for hormones and sepsis. Canatu is executing a focused roadmap, advancing from the proof-of-concept stage through the development of functional prototypes to prepare for clinical trials in selected applications, including hormones and sepsis markers, with Testosterone as the first target for commercial launch in 2030.

7. Addressing large and growing markets estimated to reach ~3B€ in 2030

Canatu is building on its unique CNT technology platform to address large and growing markets estimated to reach approximately 3B€ in 2030. In semiconductor, the total addressable market for EUV pellicles is estimated at approximately 1.5B€ in 2030, driven predominantly by advanced logic nodes. In automotive, the total addressable market is estimated at approximately 0.2B€ for ADAS camera heaters and 0.7B€ for full windshield heaters in 2030, while automotive solar cell growth is expected in the early 2030s. In Medical diagnostics, the serviceable market (SAM) for hormone testing is estimated at approximately 0.4B€, and for sepsis testing at approximately 0.3B€ in 2030.

8. Focused execution and disciplined capital allocation

Canatu prioritizes applications with the highest long‑term value creation potential, advances them through systematic validation and risk mitigation before scaling, allocates capital in a stage‑gated and milestone‑driven manner, and actively deprioritizes applications without a credible path to scale.

9. 100-150M€ revenue target and 25-30% EBIT margin in 2030

Canatu has set long‑term financial targets through the end of 2030, aiming for revenue of €100–150 million and an EBIT margin of 25–30% in 2030 (adjusted for goodwill amortization in accordance with Finnish Accounting Standards). Read more here.